Actively Recruiting

Phase 1
Age: 18Years - 45Years
All Genders
Healthy Volunteers
NCT07471932

A Study of LAD106 in Healthy Adult Participants

Led by Almirall, S.A. · Updated on 2026-03-13

93

Participants Needed

1

Research Sites

19 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

CONDITIONS

Official Title

A Study of LAD106 in Healthy Adult Participants

Who Can Participate

Age: 18Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent and willing to follow the study protocol
  • Healthy men or women aged 18 to 45 years inclusive
  • Female participants agree to use effective contraception
  • Male participants agree to use barrier protection during sexual relations with women of child-bearing potential or lactating women
  • Body mass index (BMI) between 18 and 32 kg/m2 inclusive, with a minimum bodyweight of 50 kg
  • Able to communicate well in Dutch and willing to follow study restrictions
Not Eligible

You will not qualify if you...

  • Any active or chronic disease or condition that could affect the study or pose risk, as judged by the investigator
  • Clinically significant abnormal laboratory test results
  • Use of any medications within 14 days before dosing or less than 5 half-lives, except paracetamol up to 4 g/day
  • Pregnant, breastfeeding, or planning to become pregnant during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre for Human Drug Research (CHDR) Phase 1 Unit

Leiden, Netherlands

Actively Recruiting

Loading map...

Research Team

B

Begoña Begoña

CONTACT

E

Estrella Estrella

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

12

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here